白皮书：长寿药物高级审批途径概述了这个非营利性长寿组织如何建议增加长寿药物的市场流量。 15页，但非常值得一读。
更多的人可能想阅读并签署请愿书（见下文）以及该组织的其他请愿书。请在所有社交媒体平台上宣传。
他们还提交了一份请愿书，要求增加对国家老龄化研究所（老龄生物学部）的拨款；该组织资助了理查德·米勒 (Richard Miller) 出色的 ITP 项目，该项目在严格的 3 个站点项目中测试潜在的长寿药物。我强烈建议签署该请愿书，因为我认为 NIA ITP 计划在推动长寿医学发展方面所做的工作比世界上任何人都多（他们目前的预算低于 500 万美元/年）。
要签署他们的请愿书，请单击下面标题为“请愿书”的链接，看看您可以如何提供帮助：
完整白皮书如下：
AAPLM-白皮书-Rewrite1.pdf (384.9 KB)
1 Like
A related discussion on the topic:
2 Likes
Oof. This is a toughie. There are certain medications who’s prices I believe should be subject to price controls; Insulin for example.
As a T2D, I’m currently dealing with a shortage of GLP-1s that help to control my disease because doctors are prescribing off label for weight management.
I think we need tiered controls.
Something akin to a 5+5. Five years of exclusivity, five years per treatment option ie; Tirzepatide for management of diabetes mellitus two is exclusive for five years, then they can add an additional treatment use, that gains another five year exclusivity period while Tirzepatide for T2D is subject to price controls and tiered dispensing in shortages.
2 Likes
